Navigation Links
Cynvenio Announces New LiquidBiopsy® Test for PD-L2 Expression
Date:9/6/2017

Cynvenio Biosystems, Inc., a leader in liquid biopsy testing technology for personalized medicine, today announced the launch of its PD-L2 expression test. The first of its kind, the new blood test enables highly sensitive and specific profiling and monitoring of PD-L2 expression in cancer cells recovered from a simple blood draw.

Cynvenio’s PD-L2 test is the first commercial RUO test that measures PD-L2 expression in circulating tumor cells (CTCs). Recent study data have shown that PD-L2 expression provides valuable information beyond PD-L1 positivity in predicting clinical response to pembrolizumab (Keytruda®) in head and neck squamous cell carcinoma (HNSCC)?.

“The PD-1 pathway is an important therapeutic target in various cancer types,” commented Paul Dempsey, Ph.D., Chief Scientific Officer at Cynvenio Biosystems. “Our new PD-L2 assay enables researchers to more fully understand another target and another regulator of immune evasion. This may contribute to determining which patients may better respond to checkpoint inhibition.”

For additional information or to order the test, please contact Cynvenio at 888-885-1172.

About Cynvenio Biosystems, Inc.

Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients.  Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit http://www.cynvenio.comhttp://www.clearidmonitoring.com, and http://www.liquidbiopsy.com.

?Yearley et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res. 2017 Jun 15;23(12):3158-3167.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.
LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.

Read the full story at http://www.prweb.com/releases/2017/09/prweb14665268.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Cynvenio Launches Newest LiquidBiopsy HER2 Expression Test
2. Cynvenio and Saint Luke’s Cancer Institute Launch Pilot Study to Evaluate the Potential for Early Detection of Recurrent Breast Cancer Following Therapy
3. Cynvenio Announces New LiquidBiopsy Test for PD-L1 Expression in Lung Cancer
4. Cynvenio Announces New Deployment of LiquidBiopsy® System at Leading Cancer Research Center in South Korea
5. Cynvenio Announces ClearID® Commercial Distribution Agreements for Israel, Greece, Argentina and South Korea
6. Cynvenio’s LiquidBiopsy® Platform-Derived Research Data to be Presented at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois
7. Cynvenio Research Highlights Need for Longitudinal Monitoring of Triple Negative Breast Cancer Patients
8. Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients
9. Cynvenio and TME Research Announce Neoadjuvant Breast Cancer Monitoring Study (NEAT)
10. Cynvenio Releases Two New High Recovery LiquidBiopsy® CTC Capture Kits at 2017 AACR Annual Meeting in Washington, DC.
11. Cynvenio Biosystems Announces Expansion of Payer Network with Addition of Blue Cross Blue Shield of Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... ... ... is a basic first aid supply for any work environment, but most personal eye wash ... if a dangerous substance enters both eyes? It’s one less decision, and likely quicker response ... piece. , “Whether its dirt and debris, or an acid or alkali, getting anything in ...
(Date:10/11/2017)... ... 2017 , ... Proscia Inc ., a data solutions ... “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, Managing ... how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
Breaking Biology Technology:
(Date:8/15/2017)... Va. , Aug. 15 2017   ivWatch LLC , ... of intravenous (IV) therapy, today announced receipt of its ISO 13485 ... developed by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the ... "This is ...
(Date:6/23/2017)... and ITHACA, N.Y. , ... and Cornell University, a leader in dairy research, today ... bioinformatics designed to help reduce the chances that the ... the onset of this dairy project, Cornell University has ... for Sequencing the Food Supply Chain, a food safety ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
Breaking Biology News(10 mins):